Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

What is the current share price of Vertex Pharmaceuticals (VRTX)? Vertex Pharmaceuticals's (VRTX) current share price is $488.25. This constitutes a price movement of 0.99% when compared to the share ...

My CF consists of two very rare genetic mutations. We had all heard of Trikafta being around the corner, but I had been told so many times that it wasn’t designed for someone with my mutations. So, ...

Kaftrio is sold in the US under the brand name Trikafta for patients 2 years and older who have at least one F508del mutation in the CFTR gene or a mutation in the CFTR gene that is responsive based ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...

Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...